股票代码：002562 股票简称：兄弟科技 公告编号：2023-065 债券代码：128021 债券简称：兄弟转债 兄弟科技股份有限公司 第五届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公司"） 第五届监事会第十八次会议通知于2023年7 月31日以电子邮件等形式发出，会议于2023年8月10日以现场结合通讯的方式召开。本次应参 加表决监事3人，实际参加表决监事3人，其中监事汪玮乐先生以通讯方式出席会议。本次会 议由监事会主席王程磊先生主持，公司部分高级管理人员列席会议，本次会议的召集、召开 及表决程序符合《中华人民共和国公司法》等法律、法规、规范性文件以及《公司章程》的 有关规定。 会议经认真审议，通过如下议案： 一、审议通过了《公司2023年半年度报告及其摘要》 监事会经审核后认为,《公司2023年半年度报告及其摘要》的编制和审议程序符合法律、 法规、公司章程和公司内部管理制度的各项规定；其内容和格式符合中国证监会和深圳证券 交易所的各项规定，报告内容真实、准确、完整，不存在任何虚假记载、误 ...

| 股票代码：002562 | 股票简称：兄弟科技 | 公告编号：2023-073 | | --- | --- | --- | | 债券代码：128021 | 债券简称：兄弟转债 | | 兄弟科技股份有限公司 独立董事提名人声明 提名人钱志达现就提名张福利先生为兄弟科技股份有限公司第六届董事 会独立董事候选人发表公开声明。被提名人已书面同意出任兄弟科技股份有 限公司第六届董事会独立董事候选人。本次提名是在充分了解被提名人职业、 学历、专业资格、详细的工作经历、全部兼职等情况后作出的，本提名人认 为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交 易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明如下： 一、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定 不得担任公司董事的情形。 是 □ 否 如否，请详细说明：____________________________ 二、被提名人符合中国证监会《上市公司独立董事规则》规定的独立董 事任职资格和条件。 是 □ 否 如否，请详细说明：____________________________ 三、被提名人符合公司章程规定的独立董事 ...

Financial Performance - The company's revenue for Q1 2023 was ¥675,752,812.85, a decrease of 23.14% compared to ¥879,221,669.43 in the same period last year[6] - Net profit attributable to shareholders was ¥10,718,516.56, down 89.60% from ¥103,018,237.25 year-over-year[6] - Basic and diluted earnings per share were both ¥0.01, reflecting a decrease of 90.00% from ¥0.10 in the same period last year[6] - Total operating revenue for Q1 2023 was ¥675,752,812.85, a decrease of 23.1% compared to ¥879,221,669.43 in the same period last year[22] - Net profit for Q1 2023 was ¥10,718,516.56, a significant decline of 89.6% from ¥103,018,237.25 in Q1 2022[24] - The total comprehensive income for the first quarter was -29,572,064.37 CNY, compared to 167,620,895.50 CNY in the previous year[25] Cash Flow and Assets - The net cash flow from operating activities was -¥76,031,415.32, a decline of 133.97% compared to -¥32,496,893.14 in the previous year[6] - Cash inflow from operating activities totaled 650,812,843.23 CNY, slightly up from 649,826,097.25 CNY year-over-year[26] - The company's cash and cash equivalents decreased to ¥1,943,907,962.62 from ¥2,066,298,704.11 year-over-year[20] - The ending balance of cash and cash equivalents was 383,906,155.97 CNY, down from 555,882,323.20 CNY at the end of the previous year[27] - Cash flow from investing activities generated a net inflow of 129,306,842.89 CNY, compared to 54,600,695.43 CNY in the same period last year[27] - Cash flow from financing activities resulted in a net inflow of 21,289,785.10 CNY, improving from -18,738,343.65 CNY year-over-year[27] Investments and Expenses - The company reported a significant increase in investment income, reaching ¥38,285,246.98, up 391.17% from ¥7,794,658.72 in the previous year[9] - Research and development expenses decreased by 52.37% to ¥16,052,887.38 from ¥33,703,410.70 in the same period last year[9] - The company plans to invest a total of RMB 2.5 billion in the construction of an international pharmaceutical industry base, with RMB 1.5 billion allocated for fixed asset investment and RMB 1 billion for R&D and other investments[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 56,110[12] - The company has a significant shareholder, Qian Zhida, holding 24.22% of shares, and another major shareholder, Qian Zhiming, holding 20.15%[12] - The company has pledged shares amounting to 90 million by Qian Zhida and 30 million by Qian Zhiming[12] - The company has a total of 10 major shareholders, with the top two holding over 44% of the shares combined[12] Liabilities and Tax - The company reported a significant increase in tax payable, which rose by 67.77% to ¥27,297,243.53 from ¥16,270,535.78 in the previous year[9] - Total liabilities for Q1 2023 were ¥2,266,970,405.68, down from ¥2,326,094,438.77 in the previous year[20] Other Information - The company received government subsidies amounting to ¥1,391,180.07, which are closely related to its normal business operations[7] - The company experienced a 49.79% decrease in contract liabilities, which fell to ¥11,341,546.20 from ¥22,589,429.66 due to the delivery of previously received advance payments[9] - The company is in the process of acquiring land for the pharmaceutical project, which is subject to legal bidding procedures, introducing some uncertainty regarding the timeline[14] - The first quarter report was not audited[28]

证券代码：002562 证券简称：兄弟科技 公告编号：2023-036 债券代码：128021 债券简称：兄弟转债 兄弟科技股份有限公司 会议召开时间：2023 年 4 月 20 日（星期四）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 公司董事长钱志达先生、财务中心总监张永辉先生、董事会秘书钱柳华女士、独立董事 章智勇先生（如遇特殊情况，参会人员可能进行调整）。 三、投资者参加方式 投 资 者 可 于 2023 年 4 月 20 日 （ 星 期 四 ） 15:00-17:00 通过网址 https://eseb.cn/13BlOgi1AOY 或使用微信扫描下方小程序码方式参与互动交流。投资者可 于 2023 年 4 月 20 日前进行会前提问，公司将通过本次业绩说明会，在信息披露允许范围内 就投资者普遍关注的问题进行回复与交流。欢迎广大投资者积极参与！ 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥3.41 billion, representing a 24.82% increase compared to ¥2.73 billion in 2021[27]. - The net profit attributable to shareholders for 2022 surged to approximately ¥305.53 million, a remarkable increase of 978.35% from ¥28.33 million in 2021[27]. - The net profit after deducting non-recurring gains and losses reached approximately ¥291.92 million, up 2,895.04% from ¥9.75 million in 2021[27]. - The net cash flow from operating activities for 2022 was approximately ¥150.99 million, a significant turnaround from a negative cash flow of ¥68.96 million in 2021, marking a 318.95% improvement[27]. - The basic earnings per share for 2022 increased to ¥0.29, reflecting an 866.67% rise from ¥0.03 in 2021[27]. - The total assets at the end of 2022 were approximately ¥5.70 billion, a 1.75% increase from ¥5.60 billion at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥3.37 billion, up 12.61% from ¥2.99 billion at the end of 2021[27]. - The total revenue for 2022 reached ¥3,411,357,924.54, representing a year-on-year increase of 24.82% compared to ¥2,732,994,049.94 in 2021[69]. - The pharmaceutical and chemical segment generated ¥3,304,949,711.30, accounting for 96.88% of total revenue, with a year-on-year growth of 24.50%[69]. - The revenue from pharmaceutical products was ¥2,047,916,359.21, which is 60.03% of total revenue, showing a growth of 20.38% from the previous year[69]. - The special chemicals segment reported revenue of ¥1,257,033,352.09, marking a significant increase of 31.86% year-on-year[69]. Dividend and Profit Distribution - Brother Technology reported a cash dividend of 1 RMB per 10 shares for all shareholders, with no stock bonus[4]. - The company has established a clear cash dividend policy that complies with regulations and ensures transparency in decision-making processes[186]. - The company reported a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distributable profit of 613,325,045.91 yuan, representing 100% of the profit distribution[187]. - The company has not proposed any stock dividends or capital reserve transfers, focusing solely on cash dividends for the reporting period[189]. Risk Management and Compliance - The company emphasized the importance of risk awareness regarding future plans and development strategies, highlighting potential operational risks and countermeasures[4]. - Brother Technology has a comprehensive risk management strategy outlined in the management discussion and analysis section of the report[4]. - The company faces risks from macroeconomic uncertainties, industry competition, raw material price fluctuations, and exchange rate volatility, and is implementing strategies to mitigate these risks[134]. - The company maintains compliance with various regulatory requirements, holding multiple production licenses and safety certifications valid until 2026 and beyond[48]. Corporate Governance - The annual report was approved by the board of directors, ensuring the accuracy and completeness of the financial statements[4]. - The company has established a complete independent research, production, procurement, and sales system, ensuring no reliance on the controlling shareholder[152]. - The company maintains a clear separation of assets, with independent ownership of land, factories, and equipment related to its main business[154]. - The company has an independent financial department with a dedicated financial management team, ensuring independent financial decision-making[156]. - The company emphasizes social responsibility and actively collaborates with stakeholders to promote sustainable development[150]. - The company's governance structure complies with relevant laws and regulations, with no significant discrepancies reported[150]. Research and Development - The company has a strong emphasis on research and development, particularly in organic chemistry and materials science, led by its independent director Yu Biao[166]. - The company has 20 products in the research pipeline, with 2 products already submitted for domestic drug registration[62]. - The company has established a three-tiered technology innovation mechanism, including a group research institute and various R&D centers, enhancing its technical capabilities in vitamin and leather chemical products[51]. - The company is committed to optimizing its R&D team and enhancing external resource integration to boost its technological competitiveness[133]. Market and Industry Trends - The company operates in the vitamin, flavor and fragrance, and pharmaceutical sectors, with a focus on long-term development and market expansion[36][37][38]. - The global flavor and fragrance market is projected to grow at a rate of 3.6% annually from 2021 to 2026, with significant growth expected in emerging markets like China[37]. - The global active pharmaceutical ingredient (API) market is projected to reach $245.2 billion by 2024, with a CAGR of 6.12% from 2017 to 2024[39]. - The CMO market in China is expected to maintain a CAGR of over 18% from 2020 to 2025, with a market size exceeding 120 billion yuan by 2025[41]. Operational Efficiency - The company has achieved industrial-scale production for key products like Vitamin K3 and Vitamin B1, indicating strong operational capabilities[45]. - The company holds several patents for its products, including ZL201310135494.X for Vitamin K3, showcasing its commitment to innovation and proprietary technology[45]. - The company has a total of 8,000 tons of iodine contrast agent raw material and intermediate project under construction, with a first phase capacity of 1,150 tons[48]. - The company has a total of 50,000 tons of inorganic chromium powder project currently in the construction phase[46]. Employee and Management Structure - The company has a total of 2,947 employees, with 283 in the parent company and 2,364 in major subsidiaries[181]. - The company has implemented a training plan aimed at improving employee skills and aligning with strategic goals, including specific programs for different employee levels[184]. - The company has a diverse customer base across various industries, effectively reducing operational risks associated with customer concentration[52]. - The company has developed a robust management team with strong technical and management capabilities, ensuring effective industry trend analysis and strategic planning[53]. Strategic Initiatives - The company is focusing on the emerging energy storage industry, particularly in the development of iron-chromium flow battery-related products[59]. - The company is actively pursuing strategic partnerships with suppliers to manage raw material price volatility and enhance cost control[134]. - The company aims to transition from a "manufacturing" to a "manufacturing + service" model to better meet market demands and create value for customers[125]. - The company is committed to continuous technological innovation and process optimization, maintaining a high level of automation in its production processes[46].

附件二：投资者关系活动记录表格式 证券代码： 002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 编号：2014-005 | --- | --- | --- | |------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系 | □ 特定对象调研 | □ 分析师会议 | | 活动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场调研 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名 | 方正证券 吴钊华 | | | 称及人员姓 | 方正证券 程 磊 | | | 名 | 日信证券 付豪杰 | | | 时间 | 2014 年 6 月 27 | 日 | | 地点 | 证券部会议室 | | | 上市公司接 | 董事会秘书 钱柳华 | | | 待人员姓名 | 证券投资部 朱益飞 | | | 投资者关系 | | 调研公司发展和行业情况（以调研机构 ...